BUSINESS● LOW1h ago · Nov 2, 2026, 12:30 AM
Drug maker Rohto plans clinical trials in Hong Kong as OASES’ first Japan partner
South China Morning Post · east asia
Top university research, cross-border data exchanges and access to mainland China’s large market have attracted Japanese firm Rohto Pharmaceutical to conduct clinical trials in Hong Kong, making it the first company from the country to partner with the city’s government under a flagship investment initiative. Rohto, known for its over-the-counter eye care and skincare products, is among the latest batch of 18 firms recruited by the Office for Attracting Strategic Enterprises (OASES), a...
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS22m agoWhat can Cambridge teach Hong Kong about building university towns?South China Morning PostBUSINESS1h agoHas Hong Kong’s IPO boom hit a wall – or is a year-end rush still to come?South China Morning Post